GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Quick Ratio

Fennec Pharmaceuticals (TSX:FRX) Quick Ratio : 3.27 (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Fennec Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 3.27.

Fennec Pharmaceuticals has a quick ratio of 3.27. It generally indicates good short-term financial strength.

The historical rank and industry rank for Fennec Pharmaceuticals's Quick Ratio or its related term are showing as below:

TSX:FRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.35   Med: 8   Max: 17.28
Current: 3.27

During the past 13 years, Fennec Pharmaceuticals's highest Quick Ratio was 17.28. The lowest was 1.35. And the median was 8.00.

TSX:FRX's Quick Ratio is ranked worse than
52.41% of 1553 companies
in the Biotechnology industry
Industry Median: 3.49 vs TSX:FRX: 3.27

Fennec Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Fennec Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Quick Ratio Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.11 13.39 13.54 5.67 3.27

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.67 5.16 4.74 4.39 3.27

Competitive Comparison of Fennec Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Fennec Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Quick Ratio falls into.



Fennec Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Fennec Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(36.033-2.892)/10.133
=3.27

Fennec Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(36.033-2.892)/10.133
=3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fennec Pharmaceuticals  (TSX:FRX) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Fennec Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (TSX:FRX) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Executives
Adrian J. Haigh Senior Officer
Chris Anigeron Rallis Director

Fennec Pharmaceuticals (TSX:FRX) Headlines

From GuruFocus

Forest Road Letter to Stockholders

By Business Wire Business Wire 06-01-2021